These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...
The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...
The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for ...
The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...